The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations.
 
Melissa Andrea Reimers
No Relationships to Disclose
 
Wassim Abida
Honoraria - CARET
Consulting or Advisory Role - Clovis Oncology; Janssen; MORE Health; ORIC Pharmaceuticals
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; ORIC Pharmaceuticals
 
Jonathan Chou
Stock and Other Ownership Interests - Atara Biotherapeutics; Bellicum Pharmaceuticals; Bluebird Bio; Celgene; Exelixis
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Esanik (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inovio Pharmaceuticals (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Oncolys BioPharma (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Rana R. McKay
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Exelixis; Janssen; Novartis; Tempus
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Russell Kent Pachynski
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Janssen Oncology
Travel, Accommodations, Expenses - Genentech/Roche
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Sanofi
Speakers' Bureau - AstraZeneca/MedImmune; Sanofi
Research Funding - Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst)
 
Jae Eun Choi
No Relationships to Disclose
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; Dendreon; EMD Serono; Ferring; Janssen Oncology; Medivation/Astellas; Sanofi
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Gina Neshewat
Employment - Hospital Corporation of America
 
Marcin Cieslik
No Relationships to Disclose
 
Stephanie Daignault-Newton
Consulting or Advisory Role - Augmenix
Research Funding - Bayer
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Fortis; Janssen Oncology
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Esanik; Medsyn Biopharma; OncoFusion Therapeutics; Oncopia Therapeutics; Tempus
Consulting or Advisory Role - Tempus
Patents, Royalties, Other Intellectual Property - University of Michigan royalties.
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Merck
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Prometheus (Inst); Roche (Inst)